An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically. Our results provide evidence of the therapeutic potential of this antibody cocktail.
Now
Alina Baum, Richard Copin, Dharani Ajithdoss, Anbo Zhou, Kathryn Lanza, Nicole Negron, Min Ni, Yi Wei, Gurinder S Atwal, Adelekan Oyejide, Yenny Goez-Gazi, John Dutton, Elizabeth Clemmons, Hilary M Staples, Carmen Bartley, Benjamin Klaffke, Kendra Alfson, Michal Gazi, Olga Gonzales, Edward Dick, Ricardo Carrion Jr., Laurent Pessaint, Maciel Porto, Anthony Cook, Renita Brown, Vaneesha Ali, Jack Greenhouse, Tammy Taylor, Hanne Andersen, Mark G Lewis, Neil Stahl, Andrew J Murphy, George D Yancopoulos, View ORCID ProfileChristos A Kyratsous
doi: https://doi.org/10.1101/2020.08.02.233320
No comments:
Post a Comment